The stock of Horizon Pharma PLC (HZNP) is a huge mover today! The stock is down 9.43% or $1.65 after the news, hitting $15.84 per share. About 3.04M shares traded hands. Horizon Pharma PLC (NASDAQ:HZNP) has declined 19.81% since March 27, 2015 and is downtrending. It has underperformed by 21.18% the S&P500.
The move comes after 8 months negative chart setup for the $2.57 billion company. It was reported on Oct, 30 by Barchart.com. We have $12.04 PT which if reached, will make HZNP worth $616.80 million less.
Analysts await Horizon Pharma PLC (NASDAQ:HZNP) to reports earnings on November, 5. They expect $0.41 earnings per share, up 115.79% or $0.22 from last year’s $0.19 per share. HZNP’s profit will be $66.52 million for 9.66 P/E if the $0.41 EPS becomes reality. After $0.29 actual earnings per share reported by Horizon Pharma PLC for the previous quarter, Wall Street now forecasts 41.38% EPS growth.
Out of 3 analysts covering Horizon Pharma (NASDAQ:HZNP), 2 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Horizon Pharma was the topic in 3 analyst reports since September 9, 2015 according to StockzIntelligence Inc.
According to Zacks, “Horizon Pharma plc is a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases. The company’s U.S. marketed products are ACTIMMUNE? (interferon gamma-1b), DUEXIS? (ibuprofen/famotidine), PENNSAID? (diclofenac sodium topical solution) 2% w/w, RAYOS? (prednisone) delayed-release tablets and VIMOVO? (naproxen/esomeprazole magnesium). Horizon’s global headquarters are in Dublin, Ireland.”
The institutional sentiment decreased to 1.51 in Q2 2015. Its down 0.24, from 1.75 in 2015Q1. The ratio dived, as 34 funds sold all Horizon Pharma PLC shares owned while 58 reduced positions. 65 funds bought stakes while 74 increased positions. They now own 124.42 million shares or 28.98% more from 96.46 million shares in 2015Q1.
Deerfield Management Co holds 14.19% of its portfolio in Horizon Pharma PLC for 12.26 million shares. Broadfin Capital Llc owns 4.82 million shares or 8.99% of their US portfolio. Moreover, Jw Asset Management Llc has 8.1% invested in the company for 766,724 shares. The New York-based Marble Arch Investments Lp has invested 5.65% in the stock. Healthcor Management L.P., a New York-based fund reported 3.20 million shares.
Since March 11, 2015, the stock had 0 buys, and 2 selling transactions for $1.20 million net activity. Sherman Jeffrey W sold 7,750 shares worth $246,295. Himawan Jeff sold 554,564 shares worth $12.44M.
Horizon Pharma PLC - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.